Sell Some Amylin to Panicked Shorts By James J. Cramer, RealMoney.com Columnist, 8/24/2005 9:24 AM EDT
Can't figure out how some stocks get so hated. Take this Amylin (AMLN:Nasdaq) . The short position has doubled in the last few months. Doubled! All because the scrips for its new diabetes drug Byetta may not be as good as thought.
I approach Amylin totally differently from the shorts. For some reason -- I think because it is an epidemic -- I have a lot of friends who have diabetes. Any positive for them, I cheer. It's a tough disease. When Byetta hit the market, I went out hard on Amylin, saying it should be bought. The catcalls started almost immediately, and any time the stock lifted, I saw shorts trying to knock the thing down, selling it below the bid, making it heavy at every turn.
Last night, Amylin revealed that it might have a once-a-week injectible for diabetes. The shorts weren't thinking about the possibility. Today, I see them going nuts -- the stock is much higher than it was -- covering the darned thing in early morning trading. (Only crazed short-sellers buy stocks up $6.)
What should you do if you have been listening to me on Amylin? I would sell the stock, that's what I would do, at least half the position, and play with the house's money for the rest. Think about it: This injectible is something that won't hit the market for a couple of years. You have time. Sell into the shorts' panic.
But remember, any company working on diabetes is, per se, a company you should consider because the market is much more huge than most people realize. The Amylin shorts learned that today. Sobering lesson.
News 
Market Data 
Discover 
AI
